Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!
Sep 02, 2016
Game changing agent, Opdivo, on a threshold to change standard of care in squamous cell carcinoma of the head and neck (SCCHN) According to Dr. Robert Ferris, who is vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of ...
Read More...
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Transforming Multiple Myeloma Treatment: The Promise of Novel Drug Classes
Jul 24, 2024
-Agonist.png "Toll-like Receptors Agonist")
Newsletter/Whitepaper